VANDA PHARMACEUTICALS INC. Costs and Expenses
VANDA PHARMACEUTICALS INC. (VNDA) reported Costs and Expenses of $114.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-06
- VANDA PHARMACEUTICALS INC. costs and expenses for the quarter ending 2026-06-30 was $114.34M, a 25.52% increase year-over-year.
- VANDA PHARMACEUTICALS INC. costs and expenses for the quarter ending 2026-03-31 was $101.94M, a 11.94% increase year-over-year.
- VANDA PHARMACEUTICALS INC. costs and expenses for the quarter ending 2025-12-31 was $97.57M, a 53.74% increase year-over-year.
- VANDA PHARMACEUTICALS INC. costs and expenses for the quarter ending 2025-09-30 was $87.54M, a 49.26% increase year-over-year.
- VANDA PHARMACEUTICALS INC. costs and expenses for fiscal 2025 was $367.27M, a 53.39% increase from fiscal 2024.
- VANDA PHARMACEUTICALS INC. costs and expenses for fiscal 2024 was $239.43M, a 15.90% increase from fiscal 2023.
- VANDA PHARMACEUTICALS INC. costs and expenses for fiscal 2023 was $206.59M, a 16.71% decline from fiscal 2022.
- VANDA PHARMACEUTICALS INC. costs and expenses for fiscal 2022 was $248.05M, a 9.51% increase from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 3 month as first filed | Costs and Expenses 6 month | Costs and Expenses 6 month as first filed | Costs and Expenses 9 month | Costs and Expenses 9 month as first filed | Costs and Expenses 12 month | Costs and Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $114.34M 10-Q · filed 2026-08-06 | $216.28M 10-Q · filed 2026-08-06 | $313.85M derived: sum of 3 quarters · filed 2026-08-06 | $401.39M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $101.94M 10-Q · filed 2026-05-07 | $199.51M derived: sum of 2 quarters · filed 2026-05-07 | $287.05M derived: sum of 3 quarters · filed 2026-05-07 | $378.15M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $97.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $185.11M derived: sum of 2 quarters · filed 2026-02-12 | $276.20M derived: sum of 3 quarters · filed 2026-08-06 | $367.27M 10-K · filed 2026-02-12 | ||||
| 2025-09-30 | $87.54M 10-Q · filed 2025-10-30 | $178.63M derived: sum of 2 quarters · filed 2026-08-06 | $269.70M 10-Q · filed 2025-10-30 | $333.17M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $91.09M 10-Q · filed 2026-08-06 | $182.16M 10-Q · filed 2026-08-06 | $245.63M derived: sum of 3 quarters · filed 2026-08-06 | $304.28M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $91.07M 10-Q · filed 2026-05-07 | $154.53M derived: sum of 2 quarters · filed 2026-05-07 | $213.18M derived: sum of 3 quarters · filed 2026-05-07 | $273.80M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $63.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $122.11M derived: sum of 2 quarters · filed 2026-02-12 | $182.74M derived: sum of 3 quarters · filed 2026-02-12 | $239.43M 10-K · filed 2026-02-12 | ||||
| 2024-09-30 | $58.65M 10-Q · filed 2025-10-30 | $119.27M derived: sum of 2 quarters · filed 2025-10-30 | $175.97M 10-Q · filed 2025-10-30 | $228.33M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2024-06-30 | $60.62M 10-Q · filed 2025-07-31 | $117.32M 10-Q · filed 2025-07-31 | $169.68M derived: sum of 3 quarters · filed 2026-02-12 | $214.49M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2024-03-31 | $56.70M 10-Q · filed 2025-05-08 | $109.06M derived: sum of 2 quarters · filed 2026-02-12 | $153.87M derived: sum of 3 quarters · filed 2026-02-12 | $202.79M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2023-12-31 | $52.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $97.17M derived: sum of 2 quarters · filed 2026-02-12 | $146.10M derived: sum of 3 quarters · filed 2026-02-12 | $206.59M 10-K · filed 2026-02-12 | ||||
| 2023-09-30 | $44.81M 10-Q · filed 2024-11-07 | $93.73M derived: sum of 2 quarters · filed 2024-11-07 | $154.23M 10-Q · filed 2024-11-07 | $212.08M derived: sum of 4 quarters · filed 2025-02-14 | ||||
| 2023-06-30 | $48.92M 10-Q · filed 2024-08-01 | $109.42M 10-Q · filed 2024-08-01 | $167.27M derived: sum of 3 quarters · filed 2025-02-14 | $228.68M derived: sum of 4 quarters · filed 2025-02-14 | ||||
| 2023-03-31 | $60.49M 10-Q · filed 2024-05-09 | $118.35M derived: sum of 2 quarters · filed 2025-02-14 | $179.76M derived: sum of 3 quarters · filed 2025-02-14 | $240.69M derived: sum of 4 quarters · filed 2025-02-14 | ||||
| 2022-12-31 | $57.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $119.26M derived: sum of 2 quarters · filed 2025-02-14 | $180.19M derived: sum of 3 quarters · filed 2025-02-14 | $248.05M 10-K · filed 2025-02-14 | ||||
| 2022-09-30 | $61.41M 10-Q · filed 2023-11-09 | $122.34M derived: sum of 2 quarters · filed 2023-11-09 | $190.20M 10-Q · filed 2023-11-09 | $249.58M derived: sum of 4 quarters · filed 2024-02-08 | ||||
| 2022-06-30 | $60.93M 10-Q · filed 2023-07-28 | $128.79M 10-Q · filed 2023-07-28 | $188.17M derived: sum of 3 quarters · filed 2024-02-08 | $247.45M derived: sum of 4 quarters · filed 2024-02-08 | ||||
| 2022-03-31 | $67.86M 10-Q · filed 2023-05-03 | $127.24M derived: sum of 2 quarters · filed 2024-02-08 | $186.52M derived: sum of 3 quarters · filed 2024-02-08 | $242.05M derived: sum of 4 quarters · filed 2024-02-08 | ||||
| 2021-12-31 | $59.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-08 | $118.66M derived: sum of 2 quarters · filed 2024-02-08 | $174.19M derived: sum of 3 quarters · filed 2024-02-08 | $226.52M 10-K · filed 2024-02-08 | ||||
| 2021-09-30 | $59.28M 10-Q · filed 2022-11-03 | $114.81M derived: sum of 2 quarters · filed 2022-11-03 | $167.13M 10-Q · filed 2022-11-03 | $224.34M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2021-06-30 | $55.53M 10-Q · filed 2022-08-04 | $107.86M 10-Q · filed 2022-08-04 | $165.06M derived: sum of 3 quarters · filed 2023-02-09 | $217.63M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2021-03-31 | $52.33M 10-Q · filed 2022-05-06 | $109.53M derived: sum of 2 quarters · filed 2023-02-09 | $162.10M derived: sum of 3 quarters · filed 2023-02-09 | $215.13M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2020-12-31 | $57.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $109.77M derived: sum of 2 quarters · filed 2023-02-09 | $162.80M derived: sum of 3 quarters · filed 2023-02-09 | $220.93M 10-K · filed 2023-02-09 | ||||
| 2020-09-30 | $52.57M 10-Q · filed 2021-11-04 | $105.60M derived: sum of 2 quarters · filed 2021-11-04 | $163.73M 10-Q · filed 2021-11-04 | $220.41M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2020-06-30 | $53.04M 10-Q · filed 2021-07-29 | $111.16M 10-Q · filed 2021-07-29 | $167.85M derived: sum of 3 quarters · filed 2022-02-24 | $216.57M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2020-03-31 | $58.13M 10-Q · filed 2021-05-06 | $114.81M derived: sum of 2 quarters · filed 2022-02-24 | $163.54M derived: sum of 3 quarters · filed 2022-02-24 | $212.70M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2019-12-31 | $56.69M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $105.41M derived: sum of 2 quarters · filed 2022-02-24 | $154.58M derived: sum of 3 quarters · filed 2022-02-24 | $204.38M 10-K · filed 2022-02-24 | ||||
| 2019-09-30 | $48.73M 10-Q · filed 2020-10-29 | $97.89M derived: sum of 2 quarters · filed 2020-10-29 | $147.69M 10-Q · filed 2020-10-29 | $191.58M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $49.16M 10-Q · filed 2020-08-06 | $98.97M 10-Q · filed 2020-08-06 | $142.86M derived: sum of 3 quarters · filed 2021-02-11 | $185.76M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-03-31 | $49.80M 10-Q · filed 2020-05-07 | $93.69M derived: sum of 2 quarters · filed 2021-02-11 | $136.59M derived: sum of 3 quarters · filed 2021-02-11 | $180.03M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2018-12-31 | $43.89M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $86.79M derived: sum of 2 quarters · filed 2021-02-11 | $130.23M derived: sum of 3 quarters · filed 2021-02-11 | $171.38M 10-K · filed 2021-02-11 | ||||
| 2018-09-30 | $42.90M 10-Q · filed 2019-11-07 | $86.34M derived: sum of 2 quarters · filed 2019-11-07 | $127.49M 10-Q · filed 2019-11-07 | $173.91M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-06-30 | $43.44M 10-Q · filed 2019-08-01 | $84.59M 10-Q · filed 2019-08-01 | $131.01M derived: sum of 3 quarters · filed 2020-02-26 | $177.27M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-03-31 | $41.15M 10-Q · filed 2019-05-03 | $87.58M derived: sum of 2 quarters · filed 2020-02-26 | $133.84M derived: sum of 3 quarters · filed 2020-02-26 | $177.81M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2017-12-31 | $46.43M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $92.69M derived: sum of 2 quarters · filed 2020-02-26 | $136.66M derived: sum of 3 quarters · filed 2020-02-26 | $181.99M 10-K · filed 2020-02-26 | ||||
| 2017-09-30 | $46.26M 10-Q · filed 2018-11-07 | $90.24M derived: sum of 2 quarters · filed 2018-11-07 | $135.56M 10-Q · filed 2018-11-07 | $174.46M derived: sum of 4 quarters · filed 2019-02-19 | ||||
| 2017-06-30 | $43.98M 10-Q · filed 2018-08-02 | $89.30M 10-Q · filed 2018-08-02 | $128.20M derived: sum of 3 quarters · filed 2019-02-19 | $167.33M derived: sum of 4 quarters · filed 2019-02-19 | ||||
| 2017-03-31 | $45.32M 10-Q · filed 2018-05-02 | $84.22M derived: sum of 2 quarters · filed 2019-02-19 | $123.35M derived: sum of 3 quarters · filed 2019-02-19 | $164.17M derived: sum of 4 quarters · filed 2019-02-19 | ||||
| 2016-12-31 | $38.90M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $78.03M derived: sum of 2 quarters · filed 2019-02-19 | $118.85M derived: sum of 3 quarters · filed 2019-02-19 | $164.59M 10-K · filed 2019-02-19 | ||||
| 2016-09-30 | $39.13M 10-Q · filed 2017-11-08 | $79.95M derived: sum of 2 quarters · filed 2017-11-08 | $125.69M 10-Q · filed 2017-11-08 | $172.43M derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2016-06-30 | $40.82M 10-Q · filed 2017-08-03 | $86.56M 10-Q · filed 2017-08-03 | $133.30M derived: sum of 3 quarters · filed 2018-02-15 | $171.18M derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2016-03-31 | $45.74M 10-Q · filed 2017-05-03 | $92.48M derived: sum of 2 quarters · filed 2018-02-15 | $130.36M derived: sum of 3 quarters · filed 2018-02-15 | $163.40M derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2015-12-31 | $46.74M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $84.63M derived: sum of 2 quarters · filed 2018-02-15 | $117.67M derived: sum of 3 quarters · filed 2018-02-15 | $150.11M 10-K · filed 2018-02-15 | ||||
| 2015-09-30 | $37.88M 10-Q · filed 2016-11-03 | $70.92M derived: sum of 2 quarters · filed 2016-11-03 | $103.37M 10-Q · filed 2016-11-03 | $49.04M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-06-30 | $33.04M 10-Q · filed 2016-07-28 | $65.48M 10-Q · filed 2016-07-28 | $11.16M derived: sum of 3 quarters · filed 2017-02-17 | $27.39M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-03-31 | $32.44M 10-Q · filed 2016-05-05 | -$21.88M derived: sum of 2 quarters · filed 2017-02-17 | -$5.65M derived: sum of 3 quarters · filed 2017-02-17 | $26.82M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2014-12-31 | -$54.32M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | -$38.09M derived: sum of 2 quarters · filed 2017-02-17 | -$5.63M derived: sum of 3 quarters · filed 2017-02-17 | $30.09M 10-K · filed 2017-02-17 | ||||
| 2014-09-30 | $16.23M 10-Q · filed 2015-11-04 | $48.70M derived: sum of 2 quarters · filed 2015-11-04 | $84.42M 10-Q · filed 2015-11-04 | $100.99M derived: sum of 4 quarters · filed 2016-02-12 | ||||
| 2014-06-30 | $32.47M 10-Q · filed 2015-07-31 | $68.19M 10-Q · filed 2015-07-31 | $84.76M derived: sum of 3 quarters · filed 2016-02-12 | $98.90M derived: sum of 4 quarters · filed 2016-02-12 | ||||
| 2014-03-31 | $35.72M 10-Q · filed 2015-05-07 | $52.30M derived: sum of 2 quarters · filed 2016-02-12 | $66.44M derived: sum of 3 quarters · filed 2016-02-12 | $78.17M derived: sum of 4 quarters · filed 2016-02-12 | ||||
| 2013-12-31 | $16.57M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $30.71M derived: sum of 2 quarters · filed 2016-02-12 | $42.45M derived: sum of 3 quarters · filed 2016-02-12 | $55.08M 10-K · filed 2016-02-12 | $54.28M 10-K · filed 2014-02-25 | |||
| 2013-09-30 | $14.14M 10-Q · filed 2014-10-27 | $14.11M 10-Q · filed 2013-11-08 | $25.87M derived: sum of 2 quarters · filed 2014-10-27 | $38.51M 10-Q · filed 2014-10-27 | $37.83M 10-Q · filed 2013-11-08 | $53.81M derived: sum of 4 quarters · filed 2015-03-13 | ||
| 2013-06-30 | $11.73M 10-Q · filed 2014-08-08 | $11.43M 10-Q · filed 2013-07-31 | $24.36M 10-Q · filed 2014-08-08 | $23.71M 10-Q · filed 2013-07-31 | $39.67M derived: sum of 3 quarters · filed 2015-03-13 | $53.35M derived: sum of 4 quarters · filed 2015-03-13 | ||
| 2013-03-31 | $12.63M 10-Q · filed 2014-05-08 | $12.29M 10-Q · filed 2013-05-10 | $27.93M derived: sum of 2 quarters · filed 2015-03-13 | $41.62M derived: sum of 3 quarters · filed 2015-03-13 | $58.08M derived: sum of 4 quarters · filed 2015-03-13 | |||
| 2012-12-31 | $15.30M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | $28.98M derived: sum of 2 quarters · filed 2015-03-13 | $45.45M derived: sum of 3 quarters · filed 2015-03-13 | $61.91M 10-K · filed 2015-03-13 | $60.95M 10-K · filed 2013-02-26 | |||
| 2012-09-30 | $13.68M 10-Q · filed 2013-11-08 | $30.15M derived: sum of 2 quarters · filed 2013-11-08 | $46.60M 10-Q · filed 2013-11-08 | $60.88M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-06-30 | $16.46M 10-Q · filed 2013-07-31 | $32.92M 10-Q · filed 2013-07-31 | $47.20M derived: sum of 3 quarters · filed 2014-02-25 | $58.46M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-03-31 | $16.46M 10-Q · filed 2013-05-10 | $30.74M derived: sum of 2 quarters · filed 2014-02-25 | $42.00M derived: sum of 3 quarters · filed 2014-02-25 | $50.94M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2011-12-31 | $14.28M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $25.54M derived: sum of 2 quarters · filed 2014-02-25 | $34.48M derived: sum of 3 quarters · filed 2014-02-25 | $41.98M 10-K · filed 2014-02-25 | ||||
| 2011-09-30 | $11.26M 10-Q · filed 2012-11-08 | $20.20M derived: sum of 2 quarters · filed 2012-11-08 | $27.70M 10-Q · filed 2012-11-08 | $34.66M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-06-30 | $8.94M 10-Q · filed 2012-08-03 | $16.44M 10-Q · filed 2012-08-03 | $23.40M derived: sum of 3 quarters · filed 2013-02-26 | $29.90M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-03-31 | $7.49M 10-Q · filed 2012-05-09 | $14.46M derived: sum of 2 quarters · filed 2013-02-26 | $20.96M derived: sum of 3 quarters · filed 2013-02-26 | $28.09M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2010-12-31 | $6.96M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $13.46M derived: sum of 2 quarters · filed 2013-02-26 | $20.60M derived: sum of 3 quarters · filed 2013-02-26 | $26.87M 10-K · filed 2013-02-26 | ||||
| 2010-09-30 | $6.50M 10-Q · filed 2011-11-07 | $13.64M derived: sum of 2 quarters · filed 2011-11-07 | $19.91M 10-Q · filed 2011-11-07 | |||||
| 2010-06-30 | $7.13M 10-Q · filed 2011-08-05 | $13.41M 10-Q · filed 2011-08-05 | ||||||
| 2009-12-31 | $40.50M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |